Printed in Great Britain
Interferon-Albumin Conjugate with Conserved Biological Activity (Accepted 15 December 1980) SUMMARY The heterobifunctional reagent N-succinilimidyl 3-(2-pyridylthio)propionate (SPDP) was used for the preparation of a disulphide-linked conjugate between Namalwa lymphoblastoid interferon and serum albumin. The linkage of interferon to albumin did not reduce its ability to protect MDBK cells against infection by vesicular stomatitis virus (VSV). The conjugate did not dissociate into free interferon and albumin under conditions prevailing in the assay for interferon activity. The rate of clearance of the interferon-albumin conjugate from the mouse circulatory system was somewhat slower than that of free interferon.
After intravenous, and to a lesser degree, intramuscular injection, interferon is rapidly cleared from the circulatory system (Baron et al., 1966; Finter, 1966; Cantell & Pyhala, 1973) . To maintain a concentration of a few hundred units/ml in the blood of patients treated with interferon, it is necessary to administer relatively large doses, such as 3 megaunits, two or three times weekly (Strander et al., 1973) . The phenomenon of rapid clearance or bioinactivation of interferon is in sharp contrast to the behaviour of certain blood proteins such as albumin and 7-globulins, which manifest a half-life of about I0 days (Sterling, 1951) . It was thus perceived that by forming a biologically active conjugate of interferon and albumin, it may be possible to prevent its rapid disappearance from circulation. Carlsson et al. (1978) have synthesized a new heterobifunctional reagent, N-succinilimidyl 3-(2-pyridylthio)propionate (SPDP), and used it for the preparation of disulphide-linked protein-protein conjugates. The reaction of SPDP with protein amino groups introduces 2-pyridyl disulphide structures into the protein, and the protein 2-pyridyl derivative can react with thiol-containing proteins via thiol disulphide exchange to form disulphide-linked protein-protein conjugates. By reacting serum albumin, which has a single reactive thiol group, with a 2-pyridyl disulphide derivative of Namalwa lymphoblastoid interferon (Reuveny et al., 1980) , we have prepared a biologically active interferon-albumin conjugate. The preparation and some properties of the conjugate are described.
As a first step in the preparation of the conjugate, it was necessary to prepare a 2-pyridyl disulphide derivative of interferon under conditions which would not cause excessive loss of biological activity. The effect of SPDP on the biological activity of interferon was examined as follows. To a series of tubes, each containing 2 × 106 units interferon and 1 mg protein in 1 ml buffer A (0.1 M-sodium phosphate buffer pH 7.5 containing 0.1 M-NaC1), were added increasing amounts of a solution of 2 mM-SPDP (Pharmacia) in absolute ethanol. After 30 min at 24 °C the reactions were stopped by addition of 0.3 ml 0.2 M-glycine, acting as an amino group donor to neutralize excess SPDP. The mixtures were then assayed for activity of interferon. It was found that addition of increasing amounts of SPDP caused a concomitant decrease of biological activity, 50% loss occurring at a concentration of 200 nmol/ml. This concentration of SPDP was therefore chosen for the preparation of the 2-pyridyl disulphide interferon derivative. To 1 ml buffer A containing 2 × 106 units of interferon and 1 mg protein were gradually added 200 nmol SPDP. After 30 min at 24 °C, 0.3 ml 0.2 M-glycine was added and the 2-pyridyl disulphide interferon derivative was separated from excess SPDP and glycine by gel filtration in a 15 ml bed vol. Sephadex G-25 column in buffer A. The 2-pyridyl derivative can be stored for several months at -20 °C without loss of reactivity or biological activity.
An interferon-albumin conjugate was then prepared in the following way. A solution of 1.5 ml buffer A containing 200000 units of SPDP-treated interferon (2-pyridyl disulphide interferon derivative) was mixed with 0.5 ml buffer A containing 12 mg bovine serum albumin. As a control, 1.5 ml buffer A containing 200000 units native interferon was also mixed with 0.5 ml buffer A containing 12 mg albumin. The mixtures were kept at 24 ° C for 1 h, and then each mixture was gel-filtered, in an ascending fashion, through a fully packed 240 ml bed vol. Sephacryl S-200 column (2.2 x 60 cm) in 0.1 u-potassium phosphate buffer pH 8 containing 0.5 M-NaCI and 0,04% sodium azide. Fractions of 3 ml were collected at a flow rate of 10 ml/h and assayed for interferon activity and protein.
As shown in Fig. 1 (a) , the control mixture separated into an albumin peak (fractions 34 to 45), devoid of any interferon activity, and interferon in fractions 50 to 56. The mixture containing the 2-pyridyl disulphide interferon derivative and albumin (Fig. 1 b) yielded two separate peaks of interferon activity: peak I in fractions 36 to 41, slightly ahead of the albumin peak, and peak II, in fractions 50 to 56. Of the 200000 interferon units of the mixture, about 40000 units were found in peak I and 150000 units in peak II. The results suggest that peak I constitutes a conjugate of albumin and interferon with a mol. wt. of about 90000. Peak II contains free interferon. It should be noted that the sum total of the interferon units found in peaks I and II correspond approximately to the number of units present in the mixture at the start of the conjugation reaction. This suggests that the interferon moiety, when conjugated to albumin, has a biological activity similar to that of free interferon. A similar conjugate was obtained with human serum albumin.
Since the interferon-albumin conjugate is held by a disulphide bond, it was necessary to examine whether it could dissociate under conditions prevailing during the assay for interferon activity. This was tested by adding 5000 units interferon-albumin conjugate to 1 ml Eagle's minimal medium containing 10% heat-inactivated calf serum and 106 MDBK cells (used in the assay system). The stirred cell suspension was kept at 37 °C, and 25/A amounts were removed at 1 h intervals, centrifuged and the supernatant assayed for activity of interferon. After 5 h the remaining cell suspension was centrifuged and the supernatant brought to 2 ml with buffer A and gel-filtered through the Sephacryl S-200 column. The interferon activity of the conjugate was not affected by 5 h incubation at 37 °C, and all the activity was found associated with the 90000 mol. wt. conjugate in fractions 35 to 42. No activity was detected in fractions 50 to 56, a region occupied by free interferon. The results suggest that the assayed biological activity is due to an interaction of the intact conjugate with the monolayer of MDBK cells used in the assay system.
Administration of mouse interferon into mice by the intravenous route results in rapid disappearance of the interferon from the circulation with a half-life of about 10 rain (Baron et al., 1966 : Finter, 1966 . The rate of clearance of Namalwa interferoia was now compared to that of a conjugate of Namalwa interferon and bovine serum albumin. Mice were injected intravenously, each with 10000 units interferon or interferon-albumin conjugate, and at various time intervals blood aliquots were collected and assayed for activity of interferon. The results, summarized in Fig. 2 , show that 5 min after injection of free interferon, the serum contained 4000 units/ml, but it then declined quite rapidly to 3000 units/ml at 15 min and 1000 units/ml at 30 min. At 2 h there were only 250 units/ml. On the other hand, the serum of mice receiving the interferon-albumin conjugate still contained 3000 units/ml at 1 h after injection, but this declined to 500 units/ml at 2 h and 250 units/ml at 4 h after injection.
The results suggest that the clearance of the interferon-albumin conjugate proceeds at a somewhat slower rate than that of free interferon. However, the conjugate did not manifest a stability similar to that of serum albumin.
The experimental results indicate that it is possible to use the heterobifunctional reagent SPDP for the preparation of a biologically active interferon-albumin conjugate. The reaction of SPDP with interferon, with the resulting introduction of 2-pyridyl disulphide groups into the interferon molecule, should be carefully controlled, since excessive interaction of the reagent with the protein amino groups results in inhibition of biological activity. The interaction of the interferon 2-pyridyl derivative with serum albumin, which has a single reactive thiol group, results in the formation of a disulphide-linked interferon-albumin conjugate. The yield of this reaction did not exceed 25 %, suggesting that about 25 % of the total biological activity of SPDP-treated interferon has resided in the interferon 2-pyridyl derivative, and the rest in native unreacted molecules of interferon. This assessment is supported by results of an experiment in which the fraction of free interferon which was separated from the conjugate by gel filtration (Fig. 1 b, fractions 50 to 56), was reacted with a second aliquot of albumin. Under these conditions there was no additional formation of conjugate (data not shown). It seems, therefore, that in order to increase the yield of the interferon-albumin conjugate, it may be necessary to elaborate reaction conditions in a way that will allow the introduction of 2-pyridyl disulphide groups into a larger number of interferon molecules without a concomitant deleterious effect on biological activity.
It is noteworthy that the linkage of interferon to albumin did not diminish its ability to interact with MDBK cells and induce resistance to infection with VSV. This is inferred from the results (Fig. 1) showing that practically all of the 200000 units of interferon activity present in the mixture of SPDP-treated interferon and albumin were recovered either in the conjugate (40000 units) or in the free interferon fraction (150000 units). The fact that prolonged incubation of the interferon-albumin conjugate with MDBK cells did not cause release of free interferon supports the notion that it is the albumin-bound interferon that acts directly on the cells.
It was believed that a conjugate of interferon and albumin might be endowed with a serum survival time more similar to that of albumin than to interferon. However, the disappearance of the interferon-albumin conjugate from circulation proceeded at a rate closer to that of its interferon moiety rather than to that of albumin. The causes responsible for the short survival time of the interferon-albumin conjugate in vivo are being investigated further.
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